<DOC>
	<DOCNO>NCT01843868</DOCNO>
	<brief_summary>The incidence severity chemotherapy-induced nausea vomiting ( CINV ) patient receive R-CHOP chemotherapy non-Hodgkin 's lymphoma well document . The contribution prednisolone CINV control R-CHOP regimen also unclear . This study aim evaluate overall effectiveness antiemetic control use standardise 5HT3 ( 5-Hydroxytryptamine 3 ) antagonist-containing regimen ( e.g . ondansetron ) heterogeneous group patient receive R-CHOP chemotherapy ( Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone ) .</brief_summary>
	<brief_title>Emesis Control Study Non-Hodgkin Lymphoma Patients Receiving R-CHOP</brief_title>
	<detailed_description>The aim study investigate incidence severity CINV patient receive R-CHOP treatment non-Hodgkin lymphoma standardise antiemetic prophylaxis . The study hypothesise control delayed nausea emesis suboptimal proportion patient receive R-CHOP regimen delay CINV prevent use 5HT3 antagonist beyond first day use post-chemotherapy administration . Participating institution prospectively collect data incidence CINV , severity CINV , use break through/rescue medication episode CINV uncontrolled prescribed regular antiemetic , effectiveness additional measure use previous CINV control inadequate ( example use aprepitant additional measure subsequent cycle ) major side-effects likely related antiemetic . The analysis result determine incidence severity CINV patient receive R-CHOP effectiveness prescribe antiemetic regimen . Analysis also determine control incidence CINV significant problem define subgroup patient receive R-CHOP could inform design future research ( extension current protocol ) area . Sub group investigation include patient advanced disease , abdominal involvement , receive R-CHOP every 14 day versus every 21 day ( R-CHOP14 versus R-CHOP21 ) , receive 6 8 treatment cycle R-CHOP , old patient , young female etc . A potential randomise study evaluate role aprepitant could contemplate high risk group .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Tropisetron</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Histologically confirm diagnosis non Hodgkin 's Lymphoma 2 . Newly diagnose relapsed patient chemotherapyna√Øve receive chemotherapy last 12 month . Prephase therapy prednisolone and/or vincristine &lt; one week duration prior commencement cycle 1 RCHOP permissible 3 . Intended receive RCHOP every 14 21 day minimum 3 cycle rituximab plan give CHOP day 1 fractionate day 1 21 . 4 . Males female , age 18 year old 5 . Are reasonably expect able complete CINV tool 6 . Willing complete assessment tool require study 7 . ECOG ( Eastern Cooperative Oncology Group ) performance status score 2 less 8 . Has provide write informed consent 1 . Women pregnant lactating . 2 . Previous adverse reaction standard antiemetic propose study 3 . Contraindications use antiemetic include standard care study ( e.g . cardiac , liver function ) 4 . Participation therapeutic study investigate CINV . 5 . Has clinically important abnormality determine investigator may interfere participation compliance study 6 . Presence psychological , familial , sociological geographical condition potentially hamper compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin</keyword>
	<keyword>Emesis</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Aprepitant</keyword>
</DOC>